ATR

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

Retrieved on: 
Tuesday, January 2, 2024
AstraZeneca, LLP, News, Pomerantz, Prior, Cytosorbents Corporation, Patient, Ticagrelor, ATR

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).

Key Points: 
  • NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation (“Cytosorbents” or the “Company”) (NASDAQ: CTSO).
  • The investigation concerns whether Cytosorbents and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

Retrieved on: 
Wednesday, December 13, 2023
Marketing, Exercise, Data analysis, ATR, Sale, Cytosorbents Corporation, Professional corporation, Security (finance)

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce the closing of this equity financing, with participation and support from existing institutional investors, new long-term fundamental investors, as well as all C-level executives and Board Directors, and other key leaders in the Company.

Key Points: 
  • Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce the closing of this equity financing, with participation and support from existing institutional investors, new long-term fundamental investors, as well as all C-level executives and Board Directors, and other key leaders in the Company.
  • The fundraise represents a key piece of our overall financing strategy which combines equity with non-dilutive debt.
  • Each warrant is immediately cash exercisable at an exercise price per share of $2.00 and will expire on the fifth anniversary of the original issue date.
  • The Company’s executive officers, directors, and certain non-executive officer employees of the Company also participated in the financing with a combined investment of $435,000.

Electrolyzers Market worth $57.2 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, December 20, 2023
Hydrogen, Proton, Electricity generation, FEED, Proton-exchange membrane, Government, GHG, PEM, Coal gasification, SOE, AEM, Blue, Physical, Nel ASA, SMR, EL, Air Liquide, Hybrid, NEL, Alkali, Power, ATR, IEA, Wind, Methanol, POX, Siemens Energy, CHP, Investment, Green hydrogen, AWE, Renewable energy

Based on technology, the Electrolyzers Market has been split into alkaline electrolyzers (AE), proton exchange membrane (PEM), solid oxide electrolyzers (SOE), and anion exchange membrane (AEM).

Key Points: 
  • Based on technology, the Electrolyzers Market has been split into alkaline electrolyzers (AE), proton exchange membrane (PEM), solid oxide electrolyzers (SOE), and anion exchange membrane (AEM).
  • The Electrolyzers Market for alkaline electrolyzers is anticipated to have the biggest market share over the forecast period.
  • As the need for green hydrogen grows, there is a rising emphasis on lowering the cost of electrolyzers.
  • This report segments the Electrolyzers Market based on application into four segments: energy, mobility, industrial, and grid injection.

Electrolyzers Market worth $57.2 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, December 20, 2023
Hydrogen, Proton, Electricity generation, FEED, Proton-exchange membrane, Government, GHG, PEM, Coal gasification, SOE, AEM, Blue, Physical, Nel ASA, SMR, EL, Air Liquide, Hybrid, NEL, Alkali, Power, ATR, IEA, Wind, Methanol, POX, Siemens Energy, CHP, Investment, Green hydrogen, AWE, Renewable energy

Based on technology, the Electrolyzers Market has been split into alkaline electrolyzers (AE), proton exchange membrane (PEM), solid oxide electrolyzers (SOE), and anion exchange membrane (AEM).

Key Points: 
  • Based on technology, the Electrolyzers Market has been split into alkaline electrolyzers (AE), proton exchange membrane (PEM), solid oxide electrolyzers (SOE), and anion exchange membrane (AEM).
  • The Electrolyzers Market for alkaline electrolyzers is anticipated to have the biggest market share over the forecast period.
  • As the need for green hydrogen grows, there is a rising emphasis on lowering the cost of electrolyzers.
  • This report segments the Electrolyzers Market based on application into four segments: energy, mobility, industrial, and grid injection.

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 9, 2023
HERG, Synthetic lethality, DDR, Acquisition, Safety, MD Anderson Cancer Center, WEE1, Therapy, University, PLK3, Gynecologic oncology, IND, ATR, PLK, Patient, PLK1, Division, FDA, Conference, Cardiotoxicity, Cell death, Ovarian cancer, APRE, Anemia, Poster, KOL, PLK2, AACR, Pharmaceutical industry, Aprea-Cuccaro clan

DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.

Key Points: 
  • DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update.
  • “We are very pleased by the progress of our diversified programs this past quarter.
  • “We are continuing with patients in the dose escalation portion of the study, and the dose expansion cohort is on track to be initiated in 2Q 2024.
  • The first poster included initial data from the Company’s first-in-human Phase 1/2a dose escalation trial of ATRN-119 in solid tumors.

Merlin Appoints Part 25 Certification Manager, Tim Trank, to Advance Certification of the Merlin Pilot

Retrieved on: 
Thursday, December 7, 2023
Technology, Air, Engineering, Transport, Aerospace, Manufacturing, Software, Data Management, Artificial Intelligence, Safety, Embraer, Certification, ATR, TSO, Multimedia, Weather, Honeywell, Unmasked Part 25, Part, Unit, Federal Aviation Administration, STC, Internal validity, United States Armed Forces, DER, Supplemental type certificate, Textron, PMA, Radar, Airline, Merlin, Airbus, Bombardier, Boeing

Merlin , the aviation technology company developing the world’s most capable pilot to advance the future of automated flight, today announced the appointment of Tim Trank as the company’s Part 25 Certification Manager.

Key Points: 
  • Merlin , the aviation technology company developing the world’s most capable pilot to advance the future of automated flight, today announced the appointment of Tim Trank as the company’s Part 25 Certification Manager.
  • View the full release here: https://www.businesswire.com/news/home/20231207314423/en/
    Merlin Appoints Part 25 Certification Manager, Tim Trank, to Advance Certification of the Merlin Pilot (Photo: Business Wire)
    “At Merlin, excellence in safety and innovation is our priority.
  • "Merlin is a place where great aviation professionals can apply their unique skills and expertise to transform the future of flight.
  • “Aviation certification is a complex process but essential to ensuring our skies are safe, scalable, and accessible,” said Trank.

Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers

Retrieved on: 
Monday, December 4, 2023
FDA, Health, Science, Pharmaceutical, Research, CQA, NYSE, Food, Inhaler, ATR, Multimedia, AptarGroup, Pharmaceutical industry, Pharma

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).
  • View the full release here: https://www.businesswire.com/news/home/20231204794277/en/
    Moreover, Aptar’s study will help to define the potential target product profile of low-GWP propellant MDIs to achieve comparability in critical quality attributes (CQAs) to existing MDIs.
  • Additional capabilities Aptar can provide include pilot manufacturing / process, analytical methods offering alternative pathways to clinical trials, formulation development, metering valve technology and more.
  • Moreover, the study is expected to support the ongoing FDA efforts to provide guidance on the regulatory framework with respect to the evaluation and approval of low-GWP propellant MDIs.

Global Commercial Aircraft Market 2023-2042: Strategy and Growth Outlook for Top 4 Commercial Aircraft OEMs - Airbus, Boeing, Embraer and ATR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 21, 2023
Transport, Air, Aircraft, Aviation, Key market, Embraer, MAX, Airbus A320neo family, Financial statement analysis, Competitive landscape, ATR, Commercial aviation, SAF, SWOT, Paris Air Show, Driver, EIS, Strategy, Growth, A320, Original equipment manufacturer, A321XLR, Certification, Airline, Airbus, Atlantic Ocean, Boeing

The "Global Commercial Aircraft Market - 2023-2042 - Market Dynamics, Competitive Landscape, OEMs' Strategies & Plans, Trends & Growth Opportunities and Market Outlook - Airbus, Boeing, Embraer, ATR" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Commercial Aircraft Market - 2023-2042 - Market Dynamics, Competitive Landscape, OEMs' Strategies & Plans, Trends & Growth Opportunities and Market Outlook - Airbus, Boeing, Embraer, ATR" report has been added to ResearchAndMarkets.com's offering.
  • Commercial Aviation has been on a very strong comeback trail following pandemic marked by strong passenger traffic growth and sustained growth in air cargo traffic across most key markets & regions.
  • The global airline passenger traffic is already at the pre-pandemic levels on domestic routes and international traffic, too, is in the catch-up mode.
  • On the other side of the Atlantic, Airbus' A321XLR is gearing up for certification, with its EIS in Q2 2024.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, BAY, Alzheimer's disease, AstraZeneca, Cholangiocarcinoma, Genetic testing, Ovarian cancer, Therapy, Parkinson's disease, Breast, Emotional dysregulation, Research, Virus, Clinical trial, Berzosertib, COVID-19, Viral, Ataxia telangiectasia and Rad3 related, Radiation, HIV-1, DNA repair, Vertex Pharmaceuticals, Bone marrow, Cancer, Investment, ATR, Patient, Ataxia–telangiectasia, DNA, Pharmaceutical industry, Vaccine, Bayer, Merck

A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Key Points: 
  • A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.
  • Pipeline Analysis: The report offers insights into the global ATR protein inhibitors clinical pipeline, categorized by company, indication, and phase.
  • Development Trends: ATR inhibitors are expanding their scope to include neurodegenerative diseases and viral infections, opening new avenues for treatment.
  • This innovative approach to targeting DNA damage response pathways has the potential to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.